PRESS RELEASE
Munich, 5. November 2024
Led by partner Dr. Kai-Klemens Wehlage, honert has provided comprehensive legal advice to the lead investor ATHOS in connection with the Series B financing round of Aignostics GmbH.
Aignostics is an artificial intelligence (AI) company that turns complex data into transformative insights. By combining multi-modal clinical data, industry-leading technologies and rigorous science, Aignostics develops best-in-class products and services for the next generation of precision medicine.
Other investors in the Series B Financing Round are Mayo Clinic, HTGF and existing investors such as Wellington Partners, Boehringer Ingelheim Venture Fund, CARMA Fund and the VC Fonds Technology managed by IBB Ventures.
Following the closing of the Series B Financing round, Aignostics plans to develop new product offerings for biopharmaceutical customers, drive growth in the US and develop advanced foundation models for pathology in collaboration with Mayo Clinic. The new funding will strengthen Aignostic’s Target ID, translational research and companion diagnostics (CDx) offerings and support several strategic initiatives.
Consultant ATHOS:
honert (Munich): Dr. Kai-Klemens Wehlage (lead), Judith Kutter, Veronika Nößner, Bastian Hosp (all venture capital/corporate law)